Board meeting on Nov 3 to consider Q2 FY27 results

EBITDA margin compressionResults View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹1939.20

prior close

₹1948.10

announcement price

After-mkt

timing

Nifty Midcap 150market-1.4%+2.7% vs market

Pharmaceuticals peers, median of 172sector-1.7%+2.9% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Midcap 150 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.4

15m

+0.4

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3-1.4+2.7-1.7+2.9

Next day

-0.9-2.2+1.3-2.2+1.3

-0.5-4.2+3.7-3.5+2.9

+1.1-3.2+4.3-2.4+3.5

+0.7-2.3+3.0-1.2+1.9

+1.8-2.0+3.8+0.1+1.7

+3.7-2.1+5.8-1.3+5.0

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin has informed the stock exchanges that its Board of Directors will meet on November 3, 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Q2 and H1 FY27). The insider trading window is closed from October 1 and will reopen on November 6, 2026, after 48 hours of result declaration.

Likely market impact

Routine pre-results intimation. Q2 and H1 FY27 earnings likely on or after November 3, 2026.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹7,827 Cr	₹7,048 Cr	+11.1%
Operating profit	₹1,453 Cr	₹1,917 Cr	−24.2%
Profit after tax	₹1,155 Cr	₹1,485 Cr	−22.2%
EBITDA margin	26.1%	33.2%	−7.1 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.